Sentence examples for expected complete data from inspiring English sources

The expected complete data log-likelihood is given as E W | h, g, ξ * [ ∑ j = 1 K ∑ m = 1 M log   p (θ m j, W m (j ) | η m s, ξ * ) ] = ∑ m = 1 M ∑ j = 1 K log   p (θ m j | η m s, ξ * ) p m j s, (A34 where p mjs is the sth upper-cluster dosage of the jth haplotype at marker m.

The expected complete data log-likelihood of (4) is given by Q Θ = Q 1 Θ + Q 2 Θ = ∑ i = 1 N ∑ j = 1 M n x i, y j ∑ k = 1 K P c k | x i, w j log P w j | c k P c k | x i - α ∑ i, s = 1 N ∑ k, l = 1 K D P i c k, P s c k E i s - β ∑ i, s = 1 N ∑ k, l = 1 K D P i c k, P i c l F k l using the posterior probabilities computed in the E-step.

end{aligned}In the E-step, the expected complete data log likelihood (Qleft( theta,theta ^{t-1}right) ) is computed by formulation as follows: begin{aligned} Qleft( theta,theta ^{t-1}right) =mathbb {E}left[ l_{c}left( theta right) mid D,theta ^{t-1}right].

For θ, we follow the classical approach to derive updates by optimizing the expected complete data (observed and latent) log-likelihood, conditioning on the previous estimates of ξ.

It is anticipated that there will be an attrition rate of up to 30% over the 12 months of follow-up, so we expect complete data on 238 participants.

The M-step can be interpreted as updating parameters based on the so-called expected complete-data log-likelihood.

The M-step determines θ ( i ) by maximizing the expected complete-data log-likelihood q ( θ ( i ) | θ ( i − 1 ) ) ≥ q ( θ | θ ( i − 1 ) ), ∀ θ.

The EM algorithm is an iterative method which (i) determines the expected complete-data log-likelihood given the observed data and the current parameter estimates in the E-step and (ii) maximizes the expected complete-data log-likelihood to derive new parameter estimates in the M-step.

As expected, the complete data estimation based on X 0 of the separating matrix provides again the best results.

This approach is expected to complete data published by selective, prospective, randomized clinical trials and is able to evaluate the adherence to guidelines in medical practice.

In the first scenario, data are used as a type of manufacturing input and customers expect complete, formatted, and reliable data.